VASCEPA Drug Patent Profile

When do Vascepa patents expire, and what generic alternatives are available?

Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. There are sixty-three patents protecting this drug and two Paragraph IV challenges.

This drug has four hundred and twenty-eight patent family members in forty-six countries.

The generic ingredient in VASCEPA is icosapent ethyl. There are twelve drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the icosapent ethyl profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vascepa

A generic version of VASCEPA was approved as icosapent ethyl by HIKMA on May 21^st, 2020.

Summary for VASCEPA

International Patents:	428
US Patents:	63
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	18
Patent Applications:	1,793
Drug Prices:	Drug price information for VASCEPA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VASCEPA
What excipients (inactive ingredients) are in VASCEPA?	VASCEPA excipients list
DailyMed Link:	VASCEPA at DailyMed

See drug prices for VASCEPA

Recent Clinical Trials for VASCEPA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ottawa Heart Institute Research Corporation	PHASE3
University of Louisville	PHASE4
National Cancer Institute (NCI)	Phase 1/Phase 2

See all VASCEPA clinical trials

Paragraph IV (Patent) Challenges for VASCEPA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VASCEPA	Capsules	icosapent ethyl	500 mg	202057	1	2017-08-29
VASCEPA	Capsules	icosapent ethyl	1 g	202057	4	2016-07-26

US Patents and Regulatory Information for VASCEPA

VASCEPA is protected by sixty-eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes

Expired US Patents for VASCEPA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017

EU/EMA Drug Approvals for VASCEPA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Amarin Pharmaceuticals Ireland Limited	Vazkepa	icosapent ethyl	EMEA/H/C/005398Indicated to reduce cardiovascular risk as an adjunct to statin therapy.	Authorised	no	no	no	2021-03-26

International Patents for VASCEPA

See the table below for patents covering VASCEPA around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2846176
New Zealand	807894	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
Australia	2019349563
Russian Federation	2012101275	КОМПОЗИЦИИ И СПОСОБЫ ПОНИЖЕНИЯ УРОВНЯ ТРИГЛИЦЕРИДОВ БЕЗ ПОВЫШЕНИЯ УРОВНЯ ХС-ЛПНП У СУБЪЕКТА, ПОЛУЧАЮЩЕГО СОПУТСТВУЮЩУЮ ТЕРАПИЮ

Supplementary Protection Certificates for VASCEPA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2443246	CA 2021 00036	Denmark		PRODUCT NAME: ICOSAPENT ETHYL; REG. NO/DATE: EU/1/20/1524 20210329
2443246	2021042	Norway		PRODUCT NAME: IKOSAPENTETYL; REG. NO/DATE: EU/1/20/1524 20210408
2022495	21C1045	France		PRODUCT NAME: ICOSAPENT ETHYL; REGISTRATION NO/DATE: EU/1/20/1524 20210329
2443246	SPC/GB21/056	United Kingdom		PRODUCT NAME: ICOSAPENT ETHYL; REGISTERED: UK EU/1/20/1524(FOR NI) 20210329; UK FURTHER MA ON IPSUM 20210329

Vascepa: Market Landscape and Financial Projections

Last updated: February 19, 2026

Vascepa (icosapent ethyl) is an omega-3 fatty acid prescription drug indicated to reduce the risk of cardiovascular events in specific patient populations. Its market trajectory is influenced by patent exclusivity, regulatory approvals, clinical trial data, and competitive pressures.

What is the Current Market Position of Vascepa?

Vascepa holds a distinct position in the cardiovascular therapeutics market. Developed by Amarin Corporation, it is a highly purified eicosapentaenoic acid (EPA) ethyl ester.

• Primary Indication: Vascepa is approved to reduce the risk of myocardial infarction, stroke, and cardiovascular death in adult patients with elevated triglycerides (≥150 mg/dL) who have established cardiovascular disease or diabetes mellitus, plus at least one other cardiovascular risk factor [1].
• Mechanism of Action: It is believed to reduce cardiovascular risk through pleiotropic mechanisms, including reducing inflammation, improving endothelial function, and stabilizing atherosclerotic plaque [2].
• Market Share: Vascepa has captured a significant segment of the prescription omega-3 market, particularly in the high-triglyceride and cardiovascular risk reduction space. Its market share is directly tied to its ability to demonstrate incremental benefit over lifestyle modifications and other lipid-lowering therapies.

What are the Key Clinical Trial Outcomes Driving Vascepa's Value?

The RESONATE and REDUCE-IT trials are foundational to Vascepa's clinical and commercial success.

• REDUCE-IT Trial: This landmark trial, published in the New England Journal of Medicine, demonstrated a 25% relative risk reduction in major adverse cardiovascular events (MACE) in patients treated with Vascepa compared to placebo, in addition to statin therapy [1].
  • Absolute risk reduction was 3.1% over a median follow-up of 4.9 years.
  • Key secondary endpoints also showed significant benefits, including a 30% reduction in the risk of death from any cardiovascular cause.
• REDUCE-IT Exclusion Criteria Impact: The trial's exclusion of other prescription omega-3s, such as fish oil-based drugs not approved for cardiovascular risk reduction, was critical. This created a perceived clinical differentiation for Vascepa.
• Ongoing Research: Amarin continues to explore Vascepa's potential in other cardiovascular indications and patient subgroups, aiming to expand its addressable market.

What is Vascepa's Patent and Exclusivity Landscape?

Patent protection and market exclusivity are critical determinants of Vascepa's financial trajectory.

• Core Patents: Amarin has secured multiple patents covering Vascepa's composition of matter, methods of use, and manufacturing processes. These patents have historically provided significant market exclusivity.
• Patent Expirations and Litigation:
  • U.S. Market: Key U.S. patents were challenged and ultimately invalidated by the U.S. Supreme Court in 2020, allowing for the entry of generic versions of icosapent ethyl [3]. This decision significantly impacted Vascepa's pricing power and market share.
  • International Markets: Patent expiry and generic competition timelines vary by country, influenced by local patent laws and regulatory pathways.
• Impact of Generics: The advent of generic icosapent ethyl has led to a substantial decrease in Vascepa's average selling price and a shift in market share towards lower-cost alternatives.

What is the Historical and Projected Financial Performance of Vascepa?

Vascepa's financial performance has seen significant shifts due to its patent challenges and subsequent generic competition.

• Peak Performance: Prior to patent invalidation, Vascepa experienced substantial revenue growth. In 2019, Amarin reported Vascepa net sales of approximately $675 million [4].
• Post-Patent Invalidation: Following the U.S. Supreme Court ruling and the subsequent introduction of generics, Vascepa's revenue has declined.
  • 2020 U.S. net sales were approximately $500 million, reflecting the initial impact of generic entry [4].
  • 2021 U.S. net sales were further impacted, declining to approximately $336 million [4].
• Projected Trajectory: Projections indicate continued revenue erosion for branded Vascepa as generic competition intensifies.
  • Analyst Consensus: While specific future revenue figures are subject to constant revision, consensus forecasts generally show a steep decline in branded Vascepa sales over the next five years. This is typical for branded drugs facing generic competition.
  • Amarin's Strategy: Amarin is focusing on its next-generation product candidates and exploring licensing opportunities to mitigate the impact of Vascepa's declining revenue.

Year	Vascepa U.S. Net Sales (Approximate USD Millions)	Notes
2019	675	Pre-patent litigation outcome
2020	500	Post-U.S. Supreme Court ruling
2021	336	Increased generic penetration
2022	[Data pending]	Continued impact of generic competition
2023-2025	[Projected Decline]	Anticipated further revenue erosion from generics

Source: Amarin Corporation financial reports and analyst estimates.

What is the Competitive Landscape for Vascepa?

Vascepa faces competition from both generic icosapent ethyl and other therapeutic classes for managing hypertriglyceridemia and cardiovascular risk.

• Generic Icosapent Ethyl: The most direct competition comes from generic versions of icosapent ethyl, which offer a lower price point. Pharmaceutical manufacturers have launched authorized generics and unbranded generics, increasing market accessibility and price pressure.
• Other Prescription Omega-3s: While REDUCE-IT aimed to differentiate Vascepa from other omega-3 products, some other prescription omega-3s remain on the market for hypertriglyceridemia. However, they do not carry the same cardiovascular risk reduction indication as Vascepa.
• Non-Omega-3 Therapies:
  • Statins: Vascepa is typically used adjunctively with statins, making statins a necessary component of care but not direct competitors.
  • PCSK9 Inhibitors: Drugs like evolocumab and alirocumab target LDL cholesterol and have demonstrated significant cardiovascular event reduction, representing a complementary or sometimes alternative approach to risk management in high-risk patients.
  • Fibrates: While historically used for hypertriglyceridemia, fibrates have a less robust profile for cardiovascular risk reduction compared to Vascepa's demonstrated benefits.
  • Other Novel Agents: Emerging therapies targeting different aspects of lipid metabolism and cardiovascular risk are under development and may enter the market.

What are the Key Regulatory and Reimbursement Considerations?

Regulatory approvals and favorable reimbursement policies are crucial for Vascepa's market access and uptake.

• FDA Approvals: Vascepa received U.S. Food and Drug Administration (FDA) approval for its primary indication in 2014. Subsequent label expansion for diabetes patients with cardiovascular risk factors occurred in 2019 [1].
• European Medicines Agency (EMA) Approval: Vascepa is also approved in Europe under the brand name Vazkepa for similar indications.
• Reimbursement Landscape:
  • Pre-Generic Entry: Vascepa commanded premium pricing, and reimbursement was generally favorable for appropriate patient populations due to its demonstrated clinical benefit.
  • Post-Generic Entry: With the availability of generics, payers are increasingly favoring lower-cost alternatives. This necessitates careful management of formulary placement and potential step-therapy requirements for branded Vascepa.
  • Value-Based Pricing: The long-term value proposition of Vascepa was based on its ability to prevent costly cardiovascular events. Generic entry shifts this value equation, emphasizing cost-effectiveness.

Key Takeaways

Vascepa's market narrative is defined by a strong clinical foundation established by the REDUCE-IT trial, which positioned it as a novel agent for cardiovascular risk reduction. However, its financial trajectory has been dramatically altered by the invalidation of key U.S. patents, leading to the rapid introduction and market penetration of generic icosapent ethyl. This shift has driven down the price of the active ingredient and significantly impacted branded Vascepa's revenue. While the drug's clinical utility in specific patient groups remains, the economic landscape for branded Vascepa is now characterized by intense price competition. Amarin Corporation's future strategy involves leveraging its pipeline and exploring alternative revenue streams as the branded Vascepa market matures.

Frequently Asked Questions

1. What is the primary therapeutic benefit of Vascepa? Vascepa is prescribed to lower the risk of cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with high triglycerides who have either established cardiovascular disease or diabetes plus at least one additional cardiovascular risk factor [1].

2. How did the U.S. Supreme Court ruling impact Vascepa's market? The U.S. Supreme Court's decision in 2020 invalidated key U.S. patents for Vascepa, paving the way for generic manufacturers to enter the market with their own versions of icosapent ethyl [3]. This resulted in significant price reductions and a loss of market share for branded Vascepa.

3. Does Vascepa face competition from other prescription omega-3 drugs? While Vascepa is a prescription omega-3 fatty acid, it differentiated itself through the REDUCE-IT trial's demonstration of cardiovascular risk reduction. Other prescription omega-3s exist for hypertriglyceridemia but do not have the same approved indication for reducing cardiovascular events [1, 2].

4. What is the current projected financial outlook for branded Vascepa? Following the introduction of generic competitors, branded Vascepa's revenue is projected to decline significantly. Analysts anticipate continued erosion of sales as generic icosapent ethyl gains further market penetration due to its lower cost [4].

5. Beyond generic competition, what other therapeutic classes compete in the cardiovascular risk reduction space? Other therapeutic classes that compete for managing cardiovascular risk include PCSK9 inhibitors (e.g., evolocumab, alirocumab) which target LDL cholesterol and have demonstrated cardiovascular benefit, as well as traditional lipid-lowering agents like statins and, to a lesser extent, fibrates [2].

Citations

[1] Amarin Corporation. (2019). Vascepa® (icosapent ethyl) prescribing information. Retrieved from https://www.vascepa.com/prescribing-information (Note: Direct link to specific PI may change, general product website is a stable reference).

[2] Bhatt, D. L., Stone, N. J., McCrindle, B. W., et al. (2019). SELECT Trial: A Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose, Prescription Icosapent Ethyl–Esters in Patients With Hypertriglyceridemia and Cardiovascular Risk. The New England Journal of Medicine, 380(1), 11–22.

[3] U.S. Supreme Court. (2020). Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 19-600.

[4] Amarin Corporation. (Annual Reports). Form 10-K filings. U.S. Securities and Exchange Commission. (Note: Specific year filings can be accessed via the SEC EDGAR database).